Role of thromboxane receptor on the intracellular accumulation of cis-diamminedichloroplatinum(II) in non-small-cell but not in small-cell lung cancer cell lines

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1079-1084

  Bando, Takuma ^a   Fujimura, Masaki ^a   Kasahara, Kazuo ^a   Matsuda, Tamotsu ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

cis Diamminedichloroplatinum(II); Intracellular accumulation; K+ ATPase; Lung cancer; Na+; Thromboxane receptor

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CISPLATIN; DOMITROBAN; RAMATROBAN; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG ACCUMULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FATTY ACIDS, MONOUNSATURATED; HUMANS; LUNG NEOPLASMS; RECEPTORS, THROMBOXANE; RUBIDIUM RADIOISOTOPES; TUMOR CELLS, CULTURED;

EID: 0031866144     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Loehrer PJ and Einhorn LH: Cisplatin Ann. Intern. Med 100: 704-713 (1984).
2. DeVita VT, Hellman S and Rodenberg GSA: Cancer. Principles & Practice of Oncology, 4th ed., p673-758, J B Lippincott Co, Philadelphia 1993.
3. Hospers GAP, Meuer C, Deleu L, Uges DRA, Mulder NH and DeVries EGE: A study of human small-cell lung cancer carcinoma (hSCLC) cell lines with different sensitivities to direct relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 46: 138-144 1990.
4. DeGraff A, Slebos RJC and Rodenhuis S: Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 22: 325-332, 1988.
5. Hospers GAP, Mulder NH and DeVries EGE: Mechanisms of cellular resistance to cisplatin (review). Med Oncol Tumor Pharmacother 5: 145-151, 1988.
6. Kelley SL and Rosencweig M: Resistance to platinum compounds: mechanisms and beyond. Eur J Cancer Clin Oncol 25: 1135-1140, 1989.
7. Andrews PA and Howell SB: Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1990.
8. Andrews PA, Murphy MP and Howell SB: Metallothionein mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother. Pharmacol 241: 1813-1815, 1987.
9. Tew KD, Bomber AM and Hoffman SJ: Ethacrynic acid and piriprost as enhancer of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625, 1988.
10. Basu A and Lazo JS: A hypothesis regarding the prospective role of metallothionein against the toxicity of DNA intercalating drugs. Toxicol Lett. 50: 123-125, 1990.
11. Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD and Saijo N: Determinant of drug response in a cisplatin resistant human lung cancer cell line. Jpn J Cancer Res 81: 527-535, 1990.
12. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K, Terada M and Tew KD: Glutathione-S-transferase p as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265: 4296-4301, 1990.
13. Kasahara K: Cisplatin resistance mechanisms in small cell lung cancer cell line, N231/CDDP. J Juzen Med Soc 100 858-867 (1991) (in Japanese with English abstract).
14. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T and Saijo N: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51: 3237-3242, 1991.
15. Eastman A and Schulte M: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734, 1988.
16. Timmer-Bosscha Y, Mulder NH and DeVries EGE: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 66: 227-238, 1992.
17. Gatery DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176, 1993.
18. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, Irino S: and Saijo, N. Decreased accumulation as a mechanisms of resistance to cis-diamminedichloropaltinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50: 2549-2553, 1990.
19. Horisberger J-D, Lemas V, Kraehenbuhl J-P and Rossier BC Structure-function relationship of Na, K-ATPase. Annu Rev Physiol 53: 565-584, 1991.
20. Das PK, Bray GM, Aguayo AJ and Raminski M: Diminished ouabain sensitivity sodium-potassium ATPase activity in sciatic nerves of rats with streptozotocin induced diabetes. Exp Neurol 53: 285-288, 1976.
21. + -ATPase activity in diabetic rat heart. Am J Physiol 254: C241-247, 1983.
22. +-pump concentration in skeletal muscles, heart ventricular muscle and peripheral nerves of rat. Diabetes, 36: 842-848, 1987.
23. 2 by diabetic platelet. Eur J Clin Invest 9: 223-225, 1979.
24. Awelrod, LL and LevineL: Plasma prostaglandin levels in rats with diabetes mellitus and diabetic ketoacidosis. Diabetes 31: 994-998, 1982.
25. Stein-Borda L, Franchi AM, Borda ES, Del-Castillo E, Gimeno MF and Gimeno AL: Augmented thromboxane generation by mesenteric arteries from pancreatectomized diabetic dogs is coincident with the vascular tone enhancement evoked by Na arachidonate and prostacyclin. Eur J Pharmacol 103: 211-215, 1984.
26. Jeremy JY, Thompson CS, Mikhailidis DP and Dandona P: Duration and not reverity of diabetes mellitus determines effects in prostacyclin synthesis in rat aorta, penis and bladder. Prog Lipid Res 25: 507-510, 1986.
27. 14 C-arachidonic acid in spayed rat uterus. Prostaglandins Leukot Essent Fatty Acids 48: 273-275, 1993.
28. 2 receptor antagonist. J Org Chem 56: 2122-2127, 1991.
29. Rosentreter U, Boshagen H, Seuter F, Perzborn E and Fiedler VB: Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid and comparison with its enantiomer. Arzneim.-Forsch / Drug Res 39(II): 1519-1521, 1989.
30. Bando T, Kasahara AK, Shibata K, Nakatsumi Y, Fujimura M and Matsuda T: Role of DT-diaphorase as a determinant of sensitivity to mitomycin analogue in non-small cell lung cancer cell lines, Int J Oncol 5: 819-825, 1994.
31. Bando T, Kasahara K, Shibata K, Numata Y, Heki U, Sbirasaki H, Iwasa K, Fujimura M and Matsuda T: Cytotoxicity of a novel indoloquinone EO9 in hypoxic non-small cell lung cancer cell lines. Int J Oncol 7: 789-793, 1995.
32. Bando, T, Kasahara, K, Shibata, K, Numata, Y, Heki, U, Shirasaki, H, Iwasa, K, Fujimura, M. and Matsuda, T Modulation of sensitivity to mitomycin C and its dithiol analogue by tempol in non-small cell lung cancer cell lines under hypoxia. J. Cancer Res Clin Oncol., 122, 21-26, 1996.
33. 86Rb influx in quiescent 3T3 cells. Proc Natl Acad Sci USA 72: 4492-4495, 1975.
34. Ohmori T, NIishio K, Ohta S, Kubota N, Adachi M, Komiya K and Saijo N: Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II), CDDP). Int J Cancer 57: 111-116, 1994.
35. Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T and Saijo N: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line, PC-14) and its cisplatin-resistant subline, PC-14/CDDP) Jpn J Cancer Res 84: 83-92, 1993.
36. Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, Katsura Y and Narumiya S: Thromboxane AT receptor is highly expressed in mouse impature thynocytes and mediates DNA fragmentation and apoptosis. J Exp Med 178: 1825-1830, 1993.
37. 2 receptor from human blood platelets. J Biol Chem 264: 14496-14501, 1989.
38. + -adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells. Cancer Res 51: 3677-3681, 1991.
39. Ishikaw, T and Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268: 20116-20125, 1993.
40. Fujii R, Mutoh M, Niwa K, Yamada K, Aikoh T, Nakagawa M, Kuwano M and Akiyama S: An active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn J Cancer Res 85: 426-433, 1994.
41. Fujii R, Mutoh M, Sumizawa T, Chen Z, Yoshimura: A and Akiyama S: Adenosine triphosphatase-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells J Natl Cancer Inst 86: 1781-1784, 1994.
42. 2 receptor antagonists in non-small-cell lung cancer cell lines. Br J Cancer 74: 1553-1558, 1996.
43. Fujimura M, Sasaki F, Nakatsumi Y, Takahashi Y, HIifumi S, Taga K, Mifune J, Tanaka T and Matsuda T: Effects of thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 41: 955-959, 1986.
44. Fujimura M, Nishioka AS Kumabashiri I, Matsuda T and Mifune J: Effect of aerosol administration of thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. Chest 98: 276-279, 1990.
45. Fujimura M, Sakamoto S and Matsuda T: Attenuating effect of thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma. Chest 98: 656-660, 1990.
46. 2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J Allergy Clin Immunol 87: 23-27, 1991.
47. Aviram M and Brook JG: Platelet interaction with high and low density lipoproteins. Atherosclerosis 46: 259-268, 1983.
48. Beitz J, Block H-U Beitz A, Muller G, Winkler L, Dargel R and Mest H-J: Endogenous lipoproteins modify the thromboxane formation capacity of platelets. Atherosclerosis 60: 95-99, 1986.
49. Fleisher LN, Tall AR, Witte LD, Miller RW and Cannon PJ: Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 257: 6653-6655, 1982.
50. Udvaldy M, Torok I and Rak K: Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. Thromb Res 47: 479-484, 1987.
51. Watanabe J, Wohlmann HJ, Klein RH, Collwel JA and Lopes-Virella MF: Enhancement of platelet aggregation by low-density lipoproteins from IDDM patients. Diabetes 37: 1652-1657, 1988.